Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001214659-25-014424
Filing Date
2025-09-30
Accepted
2025-09-30 20:51:09
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 22652
2 EXHIBIT 1 ex1.htm EX-1 17024
  Complete submission text file 0001214659-25-014424.txt   41223
Mailing Address 11411 SOUTHERN HIGHLANDS PARKWAY SUITE 190 LAS VEGAS NV 89141
Business Address
AULT MILTON C III (Filed by) CIK: 0001212502 (see all company filings)

State of Incorp.: DE
Type: SCHEDULE 13D/A

Mailing Address 480 PEACHTREE ROAD NE, SECOND FLOOR SUITE 103 ATLANTA GA 30326
Business Address 480 PEACHTREE ROAD NE, SECOND FLOOR SUITE 103 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Subject) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92615 | Film No.: 251362181
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)